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Class I proteins of the major histocompatibility complex play a central role in the lysis of virus infected or allogeneic cells by cytotoxic T lymphocytes (CTL) (1) . Analysis of mutant class I molecules generated in vivo or in vitro has defined residues involved in recognition by T cell receptors and monoclonal antibodies. In general the determinants recognized by antibodies (B cells) and T cells have been found to be different . For example, naturally occurring mouse and human class I variants detected by CTL display few or no changes in antibody binding (2, 3) . Substitutions at positions of variability dispersed throughout the a, and a2 domains of human and murine class I molecules have been shown to affect CTL recognition . These include positions 147-157, a region having a complex pattern of substitutions in the mouse bml mutant and in HLA-A2 and HLA-A3 subtypes, and position 116, which is altered in five of the bm mutants and in HLA-B7 subtypes (4) (5) (6) .
Similarly, mutations in class I molecules which affect antibody reactivity do not always alter the recognition by CTL (7) . For example HLA-A2 mutants obtained by negative selection with the HLA-A2, Aw69-specific monoclonal antibody, BB7 .2, were indistinguishable by CTL from the wild type molecule, although they no longer bound BB7 .2 (7) . Structural analysis indicated that changes at position 161 and in the peptide corresponding to positions 98-108 occurred separately in two of the mutants (5) . Comparison of amino acid sequences has shown that HLA-A2 and HLA-Aw69, which are the only two molecules to bind 13137 .2, share a tryptophan at position 107 within this latter region (8) . All other HLA class I molecules analyzed contain glycine at this position (9) . These results suggested that tryptophan 107 is crucial in forming the epitope recognized by BB7 .2 . Here we report experiments to directly test this hypothesis and to determine how substitution at this position affects recognition by alloreactive CTL .
Materials and Methods
Mutagenesis . Site-directed mutagenesis was performed as described (10) using a 5 .1 kb Hind III fragment of the HLA-Aw68 gene (8) 
Amino acid sequences of the a, and a2 domains of the HLA-A2/A28 family (17) and of the two mutants derived from HLA-Aw68.1 . All sequences are compared to HLA-A2.1 . pTZ 19 (Pharmacia Fine Chemicals, Piscataway, NJ) . Oligonucleotides were synthesized with an Applied Biosystems automated synthesizer.
Transfection . Class I genes were subdoned into the vector pHEBO (11) using the Hind III site. 20 jAg of DNA was transfected into 5 X 106 Hmy 2 CIR B lymphoblastoid cells by electroporation (12) . Hmy 2 CI R is an HLA-A, B-negative derivative of LicrLon Hmy 2 (13). After 4 wk in culture with 200 Icg/ml hygromycin B, >90% of transfected cells reacted with the HLA-A2, A28-specific monoclonal antibody CR11 351 (14) in flow cytometry . Cell cultures continued to stably express the transfected genes thereafter.
Analysis. Cell binding radioimmunoassays were performed with monoclonal antibodies MB40.5, PA2 .1, CR11-351, BB7 .2, and Tu160 (gift of Dr. Andreas Ziegler) as described (14, 15) . CTL were derived from the line AJY and assayed as described (16) . In inhibition assays peptides were preincubated for 30 min with 5 X 103 CTL (clones AP23.1 and ATL8.1) or 3 X 103 CTL (clone AP31.1) before addition of 103 "Cr-labeled target cells . The peptides were present throughout the assay period of 3-5 h (9) .
Results and Discussion Analysis with antibodies and CTL has defined a series of HLA-A molecules related to HLA-A2 and called the HLA-A2/A28 family (17) . The amino acid sequences of six members of this family in the two most variable domains (a, and a2) are shown in Fig. 1 . Within this family, HLA-A2.1 and HLA-Aw68 .1 are least homologous, differing by six amino acids in both the a, and a2 domains (Fig. 1) . Other members of the family (HLA-A2 .2Y, -A2 .3, -Aw68.2) contain intermediate numbers of substitutions . HLA-Aw69 is a recombinant composed of an a, domain of HLA-Aw68 .1 and a2 and as domains of HLA-A2.1 (8) . Correlation of antibody reactivity with the primary structure identified tryptophan 107 as a candidate for involvement in epitopes shared by HLA-A2 .1, -A2 .2Y, -A2 .3, and -Aw69, but not present in HLA-Aw68.1 and -Aw68.2 . This hypothesis was directly tested by introducing this residue into HLA-Aw68.1 by site-directed mutagenesis . A second mutant was generated by replacing isoleucine and methionine residues at positions 95 and 97 of HLA-Aw68.1 with the corresponding valine and arginine residues of HLA-A2 .1 (Fig. 1) .
The two mutants and the wild type HLA-Aw68 .1 gene were transfected into the B lymphoblastoid cell line Hmy2 CIR, which was chosen for its low level of class I antigen expression . The binding of monoclonal antibodies to these transfectants is shown in Fig . 2 . Monoclonal antibodies such as CR11-351, which The class II-reactive CTL line CCD was used at E/T = 1.2 . Clone AM8B.2 is reactive with an epitope in the a, domain of HLA-A2, which is shared with HLA-B17, but not HLA-Aw68 . Clone APW 15 was used as a control to show that all three transfectants bearing HLA-Aw68 .1-derived molecules could be lysed. Monoclonal antibodies directed against class I determinants present on target cells were able to block lysis by each class I-reactive clone, whereas an antibody specific for class II antigens was not (data not shown) .
are specific for epitopes shared by HLA-A2, Aw68, and Aw69, bound strongly to cells transfected with HLA-Aw68.1 and both mutant genes. This showed that the transfected genes were being expressed. The HLA-A2, Aw69-specific antibodies PA2 .1, BB7 .2, and Tu160 bound the mutant 107 transfectant, but not the HLA-Aw68.1 or mutant 95-97 transfectants . This result proves that the determinant recognized by the HLA-A2, Aw69 specific antibodies is critically dependent upon tryptophan 107 . Furthermore, the introduction of these epitopes into another class I molecule (i .e ., HLA-Aw68.1) can be effected by this single amino acid substitution . It was therefore of interest to determine if epitopes recognized by CTL were also transferred by these mutations. The transfectants expressing mutants 107 and 95-97 were tested as targets for 21 clones of CTL that lysed CIR cells transfected with the HLA-A2 .1 gene (data not shown) but did not lyse or gave weak lysis of the HLA-Aw68.1 transfectant . Four positive clones were found (Fig. 2) . Clone ATL8.1 lysed mutant 107 at a high level, and mutant 95-97 to a lesser extent . Clone AP23 .1 lysed the mutant 95-97 transfectant, but not the mutant 107 transfectants . Clone AP31 .1 lysed transfectant 107 but not transfectant 95-97, whereas clone APW.15 lysed both transfectants (Fig. 2 ). These results demonstrate that one or two amino acid substitutions in the HLA-Aw68.1 molecule are sufficient to confer reactivity with certain HLA-A2 specific CTL clones .
Analysis of the fine specificity of CTL clones ATL8.1 and AP31 .1 showed that their reactivity is distinct from that of the HLA-A2, Aw69-specific antibodies. First, neither CTL lysed cells expressing HLA-Aw69, and other CTL that recognize HLA-Aw69 failed to lyse transfectant 107. Second, these CTL lysed other members, e.g., HLA-Aw68 .2 of the HLA-A2/Aw68 family, whereas the antibodies are specific to HLA-A2 and HLA-Aw69 .
We have previously shown that tryptophan 107 is a critical residue for the inhibition of CTL given by synthetic peptides. A peptide (A2.98-113) corresponding to residues 98-113 inhibits lysis of HLA-A2 bearing targets by CTL 287 specific for HLA-A2 . In contrast, a second peptide (Aw68.98-113) derived from the same region of HLA-Aw68 .1, and which only differs by the tryptophan to glycine change at position 107 did not affect lysis (9) . The mechanism of this inhibition is not known and may occur at the surface of either the CTL and/or the target cell. To see if inhibition was dependent upon the presence of tryptophan 107 in the target class I molecule we tested the capacity of peptides A2 .98-113 and Aw68 .98-113 to inhibit the lysis of mutant transfectants 107 and 95-97 by A2-specific CTL. The lysis of an HLA-A2 .1 expressing cell line (JY) by all three CTL tested was specifically inhibited by A2 .98-113. CTL AP31 .1, which is specific for transfectant 107 but not 95-97, and CTL AP23 .1, which is specific for transfectant 95-97 but not 107 were both inhibited by peptide A2.98-113 on the appropriate transfectant target . This shows that the presence of tryptophan 107 in the target class I molecule is not a necessary requirement for the peptide inhibition . Neither is it a sufficient requirement, as shown by the results with CTL ATL8 .1, which was inhibited by the peptide on JY but not on mutant 107 .
These results show that a region encompassing residues 95-107 at the NH2-terminal end of the a2 domain of HLA-A2 is important in forming epitopes recognized both by monoclonal antibodies with polymorphic specificity and by alloreactive CTL. In the case of position 107, a single substitution is capable of introducing novel B and T cell defined epitopes of HLA-A2 into the HLAAw68.1 molecule . We do not know whether tryptophan 107 directly interacts with the combining sites of the relevant antibodies and CTL receptors or if it produces conformational changes at a separate site that is responsible for these interactions . Prediction of secondary structure shows that position 107 has a high probability of being involved in a turn at the surface of class I molecule, favoring the model of direct interaction.
Summary
We have studied the interaction of HLA class I antigens with alloreactive cytotoxic T lymphocytes and monoclonal antibodies using site-directed mutagenesis and expression of an HLA-Aw68.1 gene. Two mutants containing distinct substitutions at polymorphic residues near the NH2-terminal end of the a2 domain were made. One mutant with substitutions at positions 95 and 97 corresponding to residues found in HLA-A2.1 showed no alterations in binding of HLA-Aw68-or HLA-A2-specific monoclonal antibodies, but was reactive with some HLA-A2-specific CTL clones . A second mutant, in which glycine at position 107 was replaced with tryptophan found at that position in HLA-A2.1, was recognized by HLA-A2-specific CTL clones and HLA-A2, Aw69-specific monoclonal antibodies . Thus, substitution of a single amino acid residue at position 107 of the HLA-Aw68 .1 molecule generates an allospecific determinant shared with HLA-A2 .1 and recognized by both B and T lymphocytes.
We thank B . Sugden and H . Hayakawa for the vector pHEBO, and G . Chu for assistance with electroporation .
Received for publication 2 March 1987 and in revised form 16 April 1987. Note aded in proof Similar results have been reported by Layet et al . (18) showing that the epitope bound by the antibody BB7 .2 depends on tryptophan 107 .
